Merck & Co., Inc. (MRK): Weir Mirian M Graddick , Exe V-P, HR of Merck & Co., Inc. sold 30,000 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were sold at $57.49 per share for a total value of $1,724,553.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2016, Clark Golestani (EVP & Chief Info Officer) sold 39,877 shares at $54.67 per share price.On May 12, 2016, Michael J Holston (EVP, General Counsel) sold 100,021 shares at $54.50 per share price.Also, On Apr 14, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 131,040 shares at $56.11 per share price.On Nov 4, 2015, Wendell P Weeks (director) sold 5,000 shares at $55.53 per share price.
Merck & Co.: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Merck & Co. which led to swings in the share price. The shares opened for trading at $56.14 and hit $57.14 on the upside , eventually ending the session at $57.05, with a gain of 2.64% or 1.47 points. The heightened volatility saw the trading volume jump to 98,13,760 shares. The 52-week high of the share price is $60.07 and the company has a market cap of $157,916 M . The 52-week low of the share price is at $45.69.
Company has been under the radar of several Street Analysts.Merck & Co. is Initiated by Societe Generale to Buy and the brokerage firm has set the Price Target at $80. The Rating was issued on Apr 6, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.